Expression of adipocyte-derived leucine aminopeptidase in endometrial cancer: Association with tumor grade and CA-125

Hideo Kazeto; Seiji Nomura; Norio Ito; Tomomi Ito; Yoshiteru Watanabe; Hiroaki Kajiyama; Kiyosumi Shibata; Kazuhiko Ino; Koji Tamakoshi; Akira Hattori; Fumitaka Kikkawa; Tetsuro Nagasaka; Masafumi Tsujimoto; Shigehiko Mizutani

doi:10.1159/000074431

Expression of adipocyte-derived leucine aminopeptidase in endometrial cancer: Association with tumor grade and CA-125

Hideo Kazeto, Seiji Nomura, Norio Ito, Tomomi Ito, Yoshiteru Watanabe, Hiroaki Kajiyama, Kiyosumi Shibata, Kazuhiko Ino, Koji Tamakoshi, Akira Hattori, Fumitaka Kikkawa, Tetsuro Nagasaka, Masafumi Tsujimoto, Shigehiko Mizutani

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

Adipocyte-derived leucine aminopeptidase (A-LAP) is a novel zinc-metallopeptidase involved in angiotensin II (AngII) metabolism, cell migration and antigen presentation. These functions are implicated in the progression of cancer, whereas A-LAP expression and involvement have not been studied in any type of cancer. We investigated the expression of A-LAP in endometrial cancer as well as its association with angiogenesis and clinicopathological features. Immunohistochemical staining of 58 endometrial endometrioid adenocarcinoma specimens revealed that 37 were A-LAP immunoreactive. We also found that A-LAP staining correlated with histological tumor grade in a significant and reverse manner. In addition, serum CA-125 levels in patients with A-LAP positive cancers were significantly higher. However, contrary to our hypothesis that A-LAP suppresses angiogenic activity via AngII metabolism, A-LAP expression was not associated with the microvessel count determined by CD34 immunostaining. Our results suggest that A-LAP is involved in endometrial cancer cell growth and differentiation. However, further studies, especially of the biological roles of A-LAP, are required to confirm this notion.

Original language	English
Pages (from-to)	203-208
Number of pages	6
Journal	Tumor Biology
Volume	24
Issue number	4
DOIs	https://doi.org/10.1159/000074431
Publication status	Published - 2003
Externally published	Yes

All Science Journal Classification (ASJC) codes

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000074431

Cite this

@article{735d8eb22c5649d28d779f38870ccf0a,

title = "Expression of adipocyte-derived leucine aminopeptidase in endometrial cancer: Association with tumor grade and CA-125",

abstract = "Adipocyte-derived leucine aminopeptidase (A-LAP) is a novel zinc-metallopeptidase involved in angiotensin II (AngII) metabolism, cell migration and antigen presentation. These functions are implicated in the progression of cancer, whereas A-LAP expression and involvement have not been studied in any type of cancer. We investigated the expression of A-LAP in endometrial cancer as well as its association with angiogenesis and clinicopathological features. Immunohistochemical staining of 58 endometrial endometrioid adenocarcinoma specimens revealed that 37 were A-LAP immunoreactive. We also found that A-LAP staining correlated with histological tumor grade in a significant and reverse manner. In addition, serum CA-125 levels in patients with A-LAP positive cancers were significantly higher. However, contrary to our hypothesis that A-LAP suppresses angiogenic activity via AngII metabolism, A-LAP expression was not associated with the microvessel count determined by CD34 immunostaining. Our results suggest that A-LAP is involved in endometrial cancer cell growth and differentiation. However, further studies, especially of the biological roles of A-LAP, are required to confirm this notion.",

author = "Hideo Kazeto and Seiji Nomura and Norio Ito and Tomomi Ito and Yoshiteru Watanabe and Hiroaki Kajiyama and Kiyosumi Shibata and Kazuhiko Ino and Koji Tamakoshi and Akira Hattori and Fumitaka Kikkawa and Tetsuro Nagasaka and Masafumi Tsujimoto and Shigehiko Mizutani",

year = "2003",

doi = "10.1159/000074431",

language = "English",

volume = "24",

pages = "203--208",

journal = "Tumor Biology",

issn = "1010-4283",

publisher = "SAGE Publications Ltd",

number = "4",

}

TY - JOUR

T1 - Expression of adipocyte-derived leucine aminopeptidase in endometrial cancer

T2 - Association with tumor grade and CA-125

AU - Kazeto, Hideo

AU - Nomura, Seiji

AU - Ito, Norio

AU - Ito, Tomomi

AU - Watanabe, Yoshiteru

AU - Kajiyama, Hiroaki

AU - Shibata, Kiyosumi

AU - Ino, Kazuhiko

AU - Tamakoshi, Koji

AU - Hattori, Akira

AU - Kikkawa, Fumitaka

AU - Nagasaka, Tetsuro

AU - Tsujimoto, Masafumi

AU - Mizutani, Shigehiko

PY - 2003

Y1 - 2003

N2 - Adipocyte-derived leucine aminopeptidase (A-LAP) is a novel zinc-metallopeptidase involved in angiotensin II (AngII) metabolism, cell migration and antigen presentation. These functions are implicated in the progression of cancer, whereas A-LAP expression and involvement have not been studied in any type of cancer. We investigated the expression of A-LAP in endometrial cancer as well as its association with angiogenesis and clinicopathological features. Immunohistochemical staining of 58 endometrial endometrioid adenocarcinoma specimens revealed that 37 were A-LAP immunoreactive. We also found that A-LAP staining correlated with histological tumor grade in a significant and reverse manner. In addition, serum CA-125 levels in patients with A-LAP positive cancers were significantly higher. However, contrary to our hypothesis that A-LAP suppresses angiogenic activity via AngII metabolism, A-LAP expression was not associated with the microvessel count determined by CD34 immunostaining. Our results suggest that A-LAP is involved in endometrial cancer cell growth and differentiation. However, further studies, especially of the biological roles of A-LAP, are required to confirm this notion.

AB - Adipocyte-derived leucine aminopeptidase (A-LAP) is a novel zinc-metallopeptidase involved in angiotensin II (AngII) metabolism, cell migration and antigen presentation. These functions are implicated in the progression of cancer, whereas A-LAP expression and involvement have not been studied in any type of cancer. We investigated the expression of A-LAP in endometrial cancer as well as its association with angiogenesis and clinicopathological features. Immunohistochemical staining of 58 endometrial endometrioid adenocarcinoma specimens revealed that 37 were A-LAP immunoreactive. We also found that A-LAP staining correlated with histological tumor grade in a significant and reverse manner. In addition, serum CA-125 levels in patients with A-LAP positive cancers were significantly higher. However, contrary to our hypothesis that A-LAP suppresses angiogenic activity via AngII metabolism, A-LAP expression was not associated with the microvessel count determined by CD34 immunostaining. Our results suggest that A-LAP is involved in endometrial cancer cell growth and differentiation. However, further studies, especially of the biological roles of A-LAP, are required to confirm this notion.

UR - http://www.scopus.com/inward/record.url?scp=0345059335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345059335&partnerID=8YFLogxK

U2 - 10.1159/000074431

DO - 10.1159/000074431

M3 - Article

C2 - 14654715

AN - SCOPUS:0345059335

SN - 1010-4283

VL - 24

SP - 203

EP - 208

JO - Tumor Biology

JF - Tumor Biology

IS - 4

ER -

Expression of adipocyte-derived leucine aminopeptidase in endometrial cancer: Association with tumor grade and CA-125

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this